申请人:WHITHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
公开号:US20160031824A1
公开(公告)日:2016-02-04
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and pharmaceutical compositions thereof. The present invention also provides methods and kits using the inventive compounds and pharmaceutical compositions for treating and/or preventing diseases associated with protein aggregation, such as amyloidoses (e.g., Parkinson's disease and Alzheimer's disease), treating and/or preventing neurodegenerative diseases, treating and/or preventing diseases associated with Tar DNA binding protein 43 kDa, reducing or preventing protein aggregation, and/or modulating E3 ubiquitin ligase in a subject in need thereof.
本发明提供了式(I)的新化合物,以及其药学上可接受的盐、溶剂化合物、水合物、多晶形、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和药物组合物。本发明还提供使用这些创新化合物和药物组合物治疗和/或预防与蛋白质聚集有关的疾病的方法和工具包,例如淀粉样蛋白病(例如帕金森病和阿尔茨海默病),治疗和/或预防神经退行性疾病,治疗和/或预防与Tar DNA结合蛋白43 kDa有关的疾病,减少或预防蛋白质聚集,并/或调节需E3泛素连接酶在需要的受体中。